These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12774856)

  • 1. Working heart function in diabetes is not improved by spironolactone treatment.
    Verma S; Yuen VG; Badiwala M; Anderson TJ; McNeill JH
    Can J Physiol Pharmacol; 2003 May; 81(5):493-6. PubMed ID: 12774856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
    Miric G; Dallemagne C; Endre Z; Margolin S; Taylor SM; Brown L
    Br J Pharmacol; 2001 Jul; 133(5):687-94. PubMed ID: 11429393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes.
    Goyal BR; Solanki N; Goyal RK; Mehta AA
    J Cardiovasc Pharmacol; 2009 Dec; 54(6):502-9. PubMed ID: 19738487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
    Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus.
    Riad A; Unger D; Du J; Westermann D; Mohr Z; Sobirey M; Dorenkamp M; Schultheiss HP; Tschöpe C
    Eur J Pharmacol; 2007 Jan; 554(1):40-5. PubMed ID: 17097634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
    Mulder P; Mellin V; Favre J; Vercauteren M; Remy-Jouet I; Monteil C; Richard V; Renet S; Henry JP; Jeng AY; Webb RL; Thuillez C
    Eur Heart J; 2008 Sep; 29(17):2171-9. PubMed ID: 18586661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
    Rochetaing A; Chapon C; Marescaux L; Le Bouil A; Furber A; Kreher P
    Can J Physiol Pharmacol; 2003 Sep; 81(9):864-72. PubMed ID: 14614522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term endothelin receptor blockade improves cardiovascular function in diabetes.
    Verma S; Arikawa E; McNeill JH
    Am J Hypertens; 2001 Jul; 14(7 Pt 1):679-87. PubMed ID: 11465653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats.
    Lal A; Veinot JP; Leenen FH
    Cardiovasc Res; 2004 Dec; 64(3):437-47. PubMed ID: 15537497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ruthenium-based nitric oxide scavenger, AMD6221, augments cardiovascular responsiveness to noradrenaline in rats with streptozotocin-induced diabetes.
    Hutchings SR; Song D; Fricker SP; Pang CC
    Eur J Pharmacol; 2005 Dec; 528(1-3):132-6. PubMed ID: 16310182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.
    Thai HM; Do BQ; Tran TD; Gaballa MA; Goldman S
    J Card Fail; 2006 Apr; 12(3):240-5. PubMed ID: 16624690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage.
    Baumann M; Hermans JJ; Janssen BJ; Peutz-Kootstra C; Witzke O; Heemann U; Smits JF; Boudier HA
    J Hypertens; 2007 Dec; 25(12):2504-11. PubMed ID: 17984673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of brain natriuretic peptide on contraction and intracellular Ca2+ in ventricular myocytes from the streptozotocin-induced diabetic rat.
    Howarth FC; Al-Shamsi N; Al-Qaydi M; Al-Mazrouei M; Qureshi A; Chandranath SI; Kazzam E; Adem A
    Ann N Y Acad Sci; 2006 Nov; 1084():155-65. PubMed ID: 17151299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
    Yuan J; Jia R; Bao Y
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):118-26. PubMed ID: 17907099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A; Hayashi K; Saruta T
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of streptozotocin-induced type 1 diabetes mellitus on contraction, calcium transient, and cation contents in the isolated rat heart.
    Singh J; Chonkar A; Bracken N; Adeghate E; Latt Z; Hussain M
    Ann N Y Acad Sci; 2006 Nov; 1084():178-90. PubMed ID: 17151301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function.
    Rodrigues B; Goyal RK; McNeill JH
    J Pharmacol Exp Ther; 1986 Apr; 237(1):292-9. PubMed ID: 3958969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.